David Michael Long, JR
Physician at Horizon Hl Dr, El Cajon, CA

License number

Colorado 17870

Issued Date

Jan 9, 1973

Renew Date

May 31, 1991

Expiration Date

Dec 11, 2006

Type

Physician

Address

10988 Horizon Hills Dr, El Cajon, CA 92020

Professional information

Biocompatible, Stable And Concentrated Fluorocarbon Emulsions For Contrast Enhancement And Oxygen Transport In Internal Animal Use

US Patent:

4987154, Jan 22, 1991

Filed:

Aug 5, 1987

Appl. No.:

7/082846

Inventors:

David M. Long - El Cajon CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 4700

US Classification:

514772

Abstract:

An up to 125% fluorocarbon emulsion for use in or with animal bodies and organs thereof, maintains emulsion stability through normal sterilization procedures with selective osmotic and buffering agents, maintains the emulsion at within predetermined osmolarity levels and, when desired, free of excessive calcium precipitation, reduces in vivo and in vitro red blood cell injury, reduces adverse anemia effects, reduces viscosity and reduces the rate of oxidation, and tends to equilibrate its distribution in major body organs thereby reducing toxicity. The osmotic agents may buffer and may provide nutrient in the form of sugars. The osmotic and buffering agents can comprise, selectively, hexahydric alcohols, namely mannitol and sorbitol; certain sugars, namely glucose, mannose and fructose; along with buffering agents that will affect osmolarity including imidazole, tris(hydroxymethyl)aminomethane, sodium chloride, sodium bicarbonate, monobasic potassium phosphate, dibasic potassium phosphate, calcium chloride, magnesium sulfate, monobasic sodium phosphate, dibasic sodium phosphate or combinations of them. The emulsion may include tocopherol. A method of emulsifying the fluorocarbon includes forced flow impingement under pressure after mixing the fluorocarbon into the discontinuous phase.

Method Of Extending The Vascular Dwell-Time Of Particulate Therapeutic And Particulate Diagnostic Agents

US Patent:

5264220, Nov 23, 1993

Filed:

Nov 12, 1991

Appl. No.:

7/790855

Inventors:

David M. Long - El Cajon CA
Raymond A. Long - La Jolla CA

International Classification:

A61K 9121

US Classification:

424450

Abstract:

The present invention relates to a composition for increasing the vascular dwell-time of a particulate therapeutic or diagnostic agent in a mammal through the adjunct administration of an effective amount of the particulate therapeutic or diagnostic agent and an effective amount of a vascular dwell-time enhancing agent. Suitable therapeutic and diagnostic agents include those whose efficacy within the body is predicated on their ability to remain within or to be carried within the vascular compartment. Accordingly this method can be readily adapted for treating several diseases and disorders, including hypoxia, hypoxemia, anemia and cancer and for imaging selected regions of a mammal by various imaging techniques, including ultrasound imaging, X-ray imaging and MRI imaging.

Magnetic Resonance Imaging With Perfluorocarbon Hydrides

US Patent:

4993415, Feb 19, 1991

Filed:

Jul 12, 1990

Appl. No.:

7/551884

Inventors:

David M. Long - El Cajon CA

Assignee:

Alliance Pharmaceutical Corp. - Otisville NY

International Classification:

A61L 1500

US Classification:

128653A

Abstract:

Perfluorocarbon hydrides, either alone or in combination with other perfluorocarbon compounds, may be introduced into a non-vascular animal space as a contrast agent in magnetic resonance imaging (MRI), computed tomography (CT) or conventional x-ray procedures. In the image generated by these systems, the fluorocarbon introduced into the space is contrasted with the remaining body tissues or spaces to distinguish the fluorocarbon-occupied space from other tissues and spaces. Perfluoroctyl hydride vaporizes at body temperature, and its gas phase, which also provides in effective contrast to tissues, is disclosed in imaging areas of comparatively large void volume while using a lower fluorocarbon dose then than required for fluid fluorocarbon. Perfluorocarbon hydrides offer less radiodensity to x-ray imaging and less hydrogen density to MRI imaging, and are disclosed as diluents for perfluorocarbon bromides in applications where concentrated brominated compounds are found to cause imaging artifacts. Perfluorocarbon emulsions comprising a mixture of perfluorocarbon bromide and at least 0.

Fluorocarbon Emulsions Containing Amino Acid Based Anti-Inflamatory Agents And Buffer Systems

US Patent:

5284645, Feb 8, 1994

Filed:

Oct 4, 1989

Appl. No.:

7/417796

Inventors:

David M. Long - El Cajon CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 4904, A61K 3140, A61K 31415, A61K 31435

US Classification:

424 5

Abstract:

Disclosed are fluorocarbon emulsions comprising amino acids and substances related to amino acids, such as substituted amino acids or amphoteric groups of amino acid side chains, for example, the imidazolyl group of histidine. Emulsion formulations comprising imidazole and imidazole based drugs possess anti-inflammatory and antipyretic properties which counteract transient inflammatory responses which occur when these emulsions are administered in vivo. Lipid constituents of histidine-containing emulsions are protected against oxidation caused by free radical formation. Disclosed also are emulsion formulations buffered with amino acids comprising histidine, imidazole, and related compounds that have a buffering capacity sufficient to maintain the emulsion pH within a specified range under storage conditions and protect these emulsions from the endogenous production of acid. Disclosed also is a method of calculation which assists in the selection of an optimum buffer composition and concentration to preserve physiological compatibility and stability of the emulsions within selected pH limits.

Stable, Highly Concentrated Fluoro Carbon Emulsions

US Patent:

5393513, Feb 28, 1995

Filed:

Jul 30, 1993

Appl. No.:

8/100664

Inventors:

David M. Long - El Cajon CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 4904, A61K 3156, A61K 3135, A61B 5055

US Classification:

424 5

Abstract:

A non-toxic, brominated perfluorocarbon emulsion for internal and intravenous use in animals (including humans) is disclosed, for use as an oxygen transport medium and as a contrast enhancement medium capable of facilitating the detection of tumors and other elements within the body. This emulsion is stable and maintains its very small particle size characteristics for extended periods of time, often exceeding eighteen months after sterilization, and further may include a stabilizing component selected from the group consisting of steroids, tocopherols, cholesterols, and combinations thereof. An anti-oxidizing component enhances delivery in oxygen transport.

Method And Apparatus For Disease, Injury And Bodily Condition Screening Or Sensing

US Patent:

5697369, Dec 16, 1997

Filed:

Dec 9, 1994

Appl. No.:

8/352504

Inventors:

David M. Long - El Cajon CA
Mark L. Faupel - Conyers GA

Assignee:

Biofield Corp. - Roswell GA

International Classification:

A61B 505

US Classification:

128 6531

Abstract:

A method and apparatus for measuring biopotentials at a test site on a human or animal subject and determining therefrom the existence or status of a condition at such test site. The efficacy of treatment of a condition is monitored by comparing values obtained from biopotentials taken before treatment with those obtained during or after treatment. For disease diagnosis or screening, values obtained from biopotential measurements taken during a test period are processed in a neural network which has been programmed to recognize potential value patterns indicative of a disease condition.

Percutaneous Lymphography Using Particulate Fluorocarbon Emulsions

US Patent:

5114703, May 19, 1992

Filed:

May 29, 1990

Appl. No.:

7/530034

Inventors:

Gerald L. Wolf - Winchester MA
David M. Long - El Cajon CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

G01N 3100, G01N 2400, A61K 3128, A61K 4904

US Classification:

424 5

Abstract:

Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.

Brominated Perfluorocarbon Emulsions For Internal Animal Use For Contrast Enhancement And Oxygen Transport

US Patent:

4865836, Sep 12, 1989

Filed:

Jan 14, 1986

Appl. No.:

6/818690

Inventors:

David M. Long - El Cajon CA

Assignee:

Fluoromed Pharmaceutical, Inc. - San Diego CA

International Classification:

A61K 4904, A61K 4700

US Classification:

424 5

Abstract:

A brominated perfluorocarbon emulsion non-toxic for internal and intravenous use in animals including humans for use as an oxygen transport medium and as a tumor and other element contrast enhancement medium is stable with very small size characteristics for extended periods in excess of eighteen months and after sterilization, with a stabilizing component selected from the class comprising steroid hormones, tocopherols, cholesterols and their combinations. An anti-oxidizing component enhances delivery in oxygen transport.

Prophylaxis In The Parenteral Administration Of Particulate Dispersions In Fluorocarbon Emulsions

US Patent:

5847009, Dec 8, 1998

Filed:

Oct 15, 1993

Appl. No.:

8/138485

Inventors:

David M. Long - El Cajon CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 3102, A61K 3103, A61K 3158, A61K 3314

US Classification:

514743

Abstract:

Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.